ROIV: Settlement Windfall Will Shift Focus Toward 2026 Clinical Readouts

Analysts have increased their average price target on Roivant Sciences by about $0.04 to $35.71, citing updated models that factor in litigation settlement proceeds, the brepocitinib priority review and a lower assumed discount rate, along with adjusted profit margin and future P/E assumptions.

Analyst Commentary

Recent research updates on Roivant Sciences show a mix of optimism around litigation proceeds and key pipeline milestones, alongside some caution around how much of this is already reflected in current valuations.

Bullish Takeaways

Bullish analysts point to the US$2.25b global settlement related to Genevant and Arbutus as a key support for Roivant's valuation, since Roivant is expected to receive a substantial share of the proceeds through its ownership stakes.
Some analysts describe the settlement with Moderna as removing a major overhang, arguing that this lets investors focus more squarely on Roivant's clinical execution rather than legal risk.
The priority review for brepocitinib and its upcoming FDA action date in Q3 are framed as important milestones, with at least one bullish analyst adjusting brepocitinib forecasts to reflect a less risked view.
JPMorgan lifting its price target to US$33, citing the settlement and a cleaner story around clinical readouts, is used by bullish analysts as support that the stock's risk profile has improved.

Bearish Takeaways

Bearish analysts, or those with more neutral ratings, highlight that the settlement, while positive, may have removed a near term upside catalyst. This could limit how much additional re-rating the stock might see purely from this event.
Some caution that a portion of the litigation proceeds and brepocitinib expectations may already be embedded in current models. This could cap further valuation uplift if execution is only in line with existing assumptions.
The presence of Neutral ratings alongside higher price targets suggests that not all analysts are convinced that Roivant's risk and reward is skewed clearly in one direction, especially with key clinical outcomes still ahead.
There is also an implicit concern that, after the legal overhang is addressed, investor focus will shift entirely to trial results and commercialization. Execution risk remains in these areas and could drive volatility around the stock.

What's in the News

Roivant Sciences announced a new Phase 2b/3 clinical program for brepocitinib in lichen planopilaris, a highly morbid inflammatory scalp disorder affecting an estimated 100,000 adults in the United States, where there are currently no FDA approved therapies. (Key Developments)
Priovant, linked to Roivant, has begun enrolling subjects in a seamless Phase 2b/3 study of brepocitinib in lichen planopilaris, with first subjects enrolled in March 2026. This marks its fourth indication in late stage clinical development alongside dermatomyositis, non infectious uveitis and cutaneous sarcoidosis. (Key Developments)
The FDA granted Priority Review to brepocitinib’s New Drug Application for dermatomyositis and assigned a PDUFA target action date in the third quarter of 2026. (Key Developments)
Topline Phase 3 data in non infectious uveitis and Phase 3 study initiation in cutaneous sarcoidosis for brepocitinib are described as expected in the second half of 2026. (Key Developments)
Immunovant, related to Roivant, reported topline results from two Phase 3 studies of batoclimab in thyroid eye disease that did not meet the primary endpoint, and intends to review future plans for batoclimab development with partner HanAll Biopharma. (Key Developments)

Valuation Changes

Fair Value: Modeled fair value moved slightly from $35.67 to $35.71, a change of around 0.1%.
Discount Rate: The discount rate used in the model fell slightly from 7.61% to 7.55%.
Revenue Growth: Forecast revenue growth stayed effectively unchanged, at a modeled level of around 3.7x.
Net Profit Margin: Assumed profit margin increased from 14.83% to 18.99%.
Future P/E: The forward P/E assumption declined from 179.94x to 138.40x.

0 views

Key Takeaways

Successful clinical trials and strategic deals may improve revenue and net margins by focusing on high-value areas.
Potential in-licensing and late-stage pipeline approvals could significantly enhance earnings and portfolio sales impact.
Execution risks and competitive pressures could delay Roivant's earnings growth and profitability amidst high R&D costs and legal uncertainties.

Catalysts

About Roivant Sciences

A commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas.What are the underlying business or industry changes driving this perspective?

Roivant Sciences is focused on clinical trial execution with multiple ongoing trials, including late-stage programs like brepocitinib and batoclimab, which are expected to generate significant data readouts in the near future. Successful trial outcomes may positively impact future revenue streams.
The company has completed the Dermavant deal, potentially allowing a greater focus on clinical execution and the upside of VTAMA. This could improve net margins by refocusing capital and operational efforts on higher-value areas.
Roivant's late-stage pipeline, with potential approvals expected in the next couple of years, could lead to a projected $10 billion+ peak sales portfolio, significantly impacting earnings as these therapies are commercialized.
Business development activities with negotiations for potential in-licensing of new programs are ongoing, representing opportunities for revenue growth through the expansion of their development-stage clinical pipeline.
Roivant's commitment to returning capital to shareholders, including significant stock repurchases, is a catalyst for EPS growth, reflecting a potential undervaluation of current share prices if business fundamentals improve.

Roivant Sciences Earnings and Revenue Growth

Roivant Sciences Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Roivant Sciences's revenue will grow by 371.0% annually over the next 3 years.
Analysts are not forecasting that Roivant Sciences will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Roivant Sciences's profit margin will increase from -6079.9% to the average US Biotechs industry of 19.0% in 3 years.
If Roivant Sciences's profit margin were to converge on the industry average, you could expect earnings to reach $264.2 million (and earnings per share of $0.32) by about May 2029, up from -$809.2 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $806.4 million in earnings, and the most bearish expecting $-990.8 million.
In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 138.6x on those 2029 earnings, up from -25.2x today. This future PE is greater than the current PE for the US Biotechs industry at 17.3x.
Analysts expect the number of shares outstanding to grow by 4.81% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.55%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

Roivant Sciences faces execution risks in clinical trial management across multiple ongoing trials, which could negatively affect their revenue and delay potential earnings growth.
The competitive landscape, especially from well-established treatments like Humira, may limit Roivant's ability to capture market share quickly, impacting their expected revenue and potential profitability.
There are legal uncertainties with ongoing LNP litigation, which could result in financial liabilities or distract management, thereby affecting net margins.
Given the early development stage of many of Roivant’s drugs, there is a risk of clinical trial failures or delays, potentially impacting potential future revenues and profitability.
The projected high R&D expenses and ongoing share repurchase program could strain Roivant’s financial resources, potentially impacting their cash flow and net income.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $35.71 for Roivant Sciences based on their expectations of its future earnings growth, profit margins and other risk factors.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $41.0, and the most bearish reporting a price target of just $29.5.
In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $1.4 billion, earnings will come to $264.2 million, and it would be trading on a PE ratio of 138.6x, assuming you use a discount rate of 7.5%.
Given the current share price of $28.55, the analyst price target of $35.71 is 20.0% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Roivant Sciences?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

ROIV: Positive Phase 3 Results And Legal Uncertainty Will Shape Medium-Term Outlook